Condition: Alcohol Use Disorder · Alcoholism · Sponsor: University of Pennsylvania
This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection. Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 mL) or matching placebo. All subjects will also receive 4 sessions of Medical Management (MM). Post-treatment follow-up visits will be conducted at 4 weeks after the scheduled completion of treatment.
This description comes directly from the study's public registry record.
Timothy S Pond, MPH · 215-746-1959 · timpond@pennmedicine.upenn.edu
Rachel Weyl, BS · 215-746-1902 · rachel.weyl@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania Center for Studies of Addiction | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05028062